Thermo Fisher Scientific (TMO)

Health Care · $265B market cap · SEC CIK 0000097745

Next reports on Jan 27, 2027, after the close, with analysts expecting $7.19 in earnings per share.

52-week range $435.27 to $723.08. 1% below its 52-week high and 65% above its low.

The case for TMO

• Revenue growing 8.3% year over year.
• Within 1% of its 52-week high: the trend is up.

The case against

• Expensive for its growth: 37.4× earnings, where 6% a year of growth would justify about 17×.
• Long-term debt of $39.2B would take 5 years of operating cash flow to repay.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Thermo Fisher Scientific's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Thermo Fisher Scientific says it does

Description of Business Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. We continuously increase our depth of capabilities across our broad portfolio of innovative products and services and…

Risk factors TMO lists in its 10-K

• Our growth would be impacted if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality
• Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate
• Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations
• Demand for some of our products depends on capital spending policies of our customers and on government funding policies
• We are subject to risks associated with public health emergencies, pandemics, epidemics, or other health outbreaks
• We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products and services by competitors and maintain quality to remain competitive
• It may be difficult for us to implement our strategies for improving internal growth
• Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business
• Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies
• Our success is largely dependent upon our ability to attract and retain a highly qualified workforce, comprised of scientific, technical, clinical, and management talent
• We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows
• Increasing attention to sustainability matters may impact our business, financial results, stock price or reputation
• New governmental regulations or changes in existing governmental regulations may reduce demand for our products or increase our expenses
• Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer
• A violation of data privacy or data protection laws could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business
• We are subject to product and other liability risks for which we may not have adequate insurance coverage
• We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies
• Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties
• Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings

Filings

Other Health Care companies